[go: up one dir, main page]

MX2024003068A - Profarmaco de derivados de pirrolidona como activador de glucocinasa. - Google Patents

Profarmaco de derivados de pirrolidona como activador de glucocinasa.

Info

Publication number
MX2024003068A
MX2024003068A MX2024003068A MX2024003068A MX2024003068A MX 2024003068 A MX2024003068 A MX 2024003068A MX 2024003068 A MX2024003068 A MX 2024003068A MX 2024003068 A MX2024003068 A MX 2024003068A MX 2024003068 A MX2024003068 A MX 2024003068A
Authority
MX
Mexico
Prior art keywords
prodrug
glucokinase activator
compound
formula
pyrrolidone derivatives
Prior art date
Application number
MX2024003068A
Other languages
English (en)
Inventor
Jin She
Li Chen
Guanghua Lv
Xiangle Jin
Fuxing Tang
Original Assignee
Hua Medicine Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hua Medicine Shanghai Ltd filed Critical Hua Medicine Shanghai Ltd
Publication of MX2024003068A publication Critical patent/MX2024003068A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente divulgación proporciona un compuesto de fórmula (I), o un producto isotópicamente marcado, un enantiómero, un diastereoisómero o una sal farmacéuticamente aceptable del mismo; una composición farmacéutica que comprende un compuesto de fórmula (I); y el uso de un compuesto de fórmula (I) o una composición farmacéutica del mismo en el tratamiento de la diabetes mellitus y síntomas relacionados.
MX2024003068A 2021-09-15 2022-09-15 Profarmaco de derivados de pirrolidona como activador de glucocinasa. MX2024003068A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111079620 2021-09-15
CN202211093895 2022-09-08
PCT/CN2022/118947 WO2023040937A1 (en) 2021-09-15 2022-09-15 Prodrug of pyrrolidone derivatives as glucokinase activator

Publications (1)

Publication Number Publication Date
MX2024003068A true MX2024003068A (es) 2024-03-27

Family

ID=83505858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003068A MX2024003068A (es) 2021-09-15 2022-09-15 Profarmaco de derivados de pirrolidona como activador de glucocinasa.

Country Status (18)

Country Link
US (2) US12054477B2 (es)
EP (1) EP4244221B1 (es)
JP (1) JP7751731B2 (es)
KR (1) KR20240044465A (es)
CN (1) CN117940419A (es)
AR (1) AR127064A1 (es)
AU (1) AU2022346020A1 (es)
CA (1) CA3231566A1 (es)
CL (1) CL2024000738A1 (es)
CO (1) CO2024002748A2 (es)
EC (1) ECSP24020925A (es)
GE (1) GEAP202416483A (es)
IL (1) IL311237A (es)
MX (1) MX2024003068A (es)
PE (1) PE20240933A1 (es)
TW (1) TW202328107A (es)
WO (1) WO2023040937A1 (es)
ZA (1) ZA202402086B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020451966A1 (en) * 2020-06-04 2023-01-19 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with hepatic impairment
AR132113A1 (es) * 2023-03-13 2025-05-28 Hua Medicine Shanghai Ltd Forma sólida de derivados de pirrolidona como activador de glucoquinasa
WO2024251159A1 (zh) 2023-06-06 2024-12-12 华领医药技术（上海）有限公司 用于认知障碍和神经退行性疾病的葡萄糖激酶激活剂
WO2025128941A1 (en) 2023-12-14 2025-06-19 Hua Medicine USA Inc. Pharmaceutical formulation comprising glucokinase activator and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2009126782A1 (en) 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
EP2276479B1 (en) * 2008-04-15 2014-07-02 SineVir Therapeutics LLC Prodrugs of neuraminidase inhibitors
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772541B2 (en) 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
SG11201504951TA (en) * 2012-12-25 2015-07-30 Hua Medicine Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
HK1252693A1 (zh) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
AU2017376544C1 (en) 2016-12-15 2021-06-24 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor
MA50014A (fr) 2017-04-20 2020-07-08 Leidos Biomedical Res Inc Modulateurs de k-ras
US11992477B2 (en) * 2018-05-31 2024-05-28 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US11008303B2 (en) 2019-01-30 2021-05-18 Insilico Medicine Ip Limited TLR 9 inhibitors
US10689360B1 (en) 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
WO2022040604A1 (en) 2020-08-21 2022-02-24 BioAge Labs, Inc. Use of dp1 receptor antagonists for the treatment of viral respiratory tract infections and dysregulated immune response in aged and aging patients

Also Published As

Publication number Publication date
CN117940419A (zh) 2024-04-26
GEAP202416483A (en) 2024-04-25
WO2023040937A1 (en) 2023-03-23
IL311237A (en) 2024-05-01
AU2022346020A1 (en) 2024-03-21
AR127064A1 (es) 2023-12-13
PE20240933A1 (es) 2024-04-30
US12054477B2 (en) 2024-08-06
EP4244221A1 (en) 2023-09-20
CL2024000738A1 (es) 2024-08-30
EP4244221B1 (en) 2025-12-10
US20230322738A1 (en) 2023-10-12
ZA202402086B (en) 2024-11-27
CO2024002748A2 (es) 2024-03-27
KR20240044465A (ko) 2024-04-04
JP7751731B2 (ja) 2025-10-08
JP2024533536A (ja) 2024-09-12
TW202328107A (zh) 2023-07-16
US20240336597A1 (en) 2024-10-10
CA3231566A1 (en) 2023-03-23
ECSP24020925A (es) 2024-04-30

Similar Documents

Publication Publication Date Title
CL2024000738A1 (es) Profármaco de derivados de pirrolidona como activador de glucocinasa
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
CL2024000593A1 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
CL2010001358A1 (es) Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.
DOP2012000025A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteina
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP109934A (es) Compuesto - 946
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CO2022004978A2 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica